Lenvatinib

Lenvatinib is a potent inhibitor of multiple receptor tyrosine kinases, with IC₅₀ values of  22 nM, 4 nM, 5.2 nM, 39 nM and 35 nM on VEGFR-1, VEGFR-2, VEGFR-3, PDGFRβ and RET, respectively. It inhibits SCF- and VEGF-induced angiogenesis of human umbilical vein endothelial cells that express the SCF receptor KIT, with IC₅₀ values of 5.2 nM and 5.1 nM, respectively. Lenvatinib inhibits tumor growth in the human small cell lung cancer H146 xenograft model.